Roche

(Image: Getty/Shidlovski)

Genentech taps Halozyme’s tech in Herceptin Hylecta

By Maggie Lynch

Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.

Pharma appointments create controversy

Hired and Retired: Controversies at the top

By Ben Hargreaves

The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.